Calls For NICE Reforms Intensify After Early Enzalutamide Use Rejected
This article was originally published in The Pink Sheet Daily
The U.K.’s health technology assessment body disappoints patient groups with three draft appraisals for prostate cancer therapies.
You may also be interested in...
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.